Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma.
Jason A ChesneyAntoni RibasGeorgina V LongJoanne M JeterReinhard DummerIgor PuzanovChristoph HoellerThomas F GajewskiRalf GutzmerPiotr Lukasz RutkowskiLev DemidovPetr ArenbergerSang Joon ShinPier Francesco FerrucciAndrew M HaydonJohn R HyngstromJohannes V van ThienenSebastian HaferkampJosep Malvehy GuileraBernardo Leon RapoportAri M VanderWaldeScott J DiedeJames R AndersonSheryl TreichelEdward L ChanSumita BhattaJennifer GansertFrank Stephen HodiHelen J GogasPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
T-VEC-pembrolizumab did not significantly improve PFS or OS compared with placebo-pembrolizumab. Safety results of the T-VEC-pembrolizumab combination were consistent with the safety profiles of each agent alone.